AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11168669 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% gentian violet applied twice a day for nasal lesions (9 cases)
Number of subjects: 37
Study 11168669 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentian violet (MIC against MRSA)
Number of subjects: 37
Study 8779402 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ml bupivacaine 0.25% + 0.1 mg fentanyl (B + F group)
Number of subjects: 53
Study 8779402 — intervention group
Group type: COMPARATOR
Intervention: 8 ml bupivacaine 0.25% + 2 ml saline (BUP group)
Number of subjects: 53
Study 8779402 — intervention group
Group type: EXPERIMENTAL
Intervention: B + F group
Number of subjects: 53
Study 8779402 — intervention group
Group type: COMPARATOR
Intervention: BUP group
Number of subjects: 53
Study 1549942 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (mean duration 40 min)
Number of subjects: 21
Study 1549942 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-methohexitone (30 min)
Number of subjects: 21
Study 1549942 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (30 min)
Number of subjects: 21
Study 4089013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 1
Study 4089013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 31105044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed diet
Number of subjects: 20
Study 31105044 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed diet
Number of subjects: 20
Study 29601997 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) restricted diet (<25:>50:25% daily calories from CHO: fat: protein)
Number of subjects: 40
Study 29601997 — intervention group
Group type: COMPARATOR
Intervention: Fat restricted diet (55:20:25% daily calories from CHO: fat: protein)
Number of subjects: 40
Study 29601997 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) restricted diet
Number of subjects: 40
Study 29601997 — intervention group
Group type: COMPARATOR
Intervention: Fat restricted diet
Number of subjects: 40
Study 27814861 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) with unloading techniques on the piriformis muscle, applied for three days
Number of subjects: 51
Study 27814861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 24641783 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered rotating-oscillating toothbrush with repeated oral hygiene instructions (OHI) and motivation (Group E1)
Number of subjects: 60
Study 24641783 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush with repeated oral hygiene instructions (OHI) and motivation (Group M1)
Number of subjects: 60
Study 24641783 — intervention group
Group type: COMPARATOR
Intervention: Powered rotating-oscillating toothbrush without repeated oral hygiene instructions (OHI) and motivation (Group E2)
Number of subjects: 60
Study 24641783 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush without repeated oral hygiene instructions (OHI) and motivation (Group M2)
Number of subjects: 60
Study 22256777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure aglycone form of genistein (GEN)
Number of subjects: 0
Study 22256777 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucoside form of genistein (GEN)
Number of subjects: 0
Study 22256777 — intervention group
Group type: COMPARATOR
Intervention: Aglycone form of genistein (GEN)
Number of subjects: 0
Study 20585816 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exercise every day
Number of subjects: 120
Study 20585816 — intervention group
Group type: COMPARATOR
Intervention: Joint mobilization by physical therapists in the hospital setting
Number of subjects: 120
Study 20585816 — intervention group
Group type: COMPARATOR
Intervention: Group with more than 7 months of the condition
Number of subjects: 120
Study 20585816 — intervention group
Group type: COMPARATOR
Intervention: Dominant-handed group
Number of subjects: 120
Study 20585816 — intervention group
Group type: COMPARATOR
Intervention: Age group 71 years and above
Number of subjects: 120
Study 20585816 — intervention group
Group type: COMPARATOR
Intervention: Frequency of sessions for joint mobilization
Number of subjects: 120
Study 18284435 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg/day) for 12 weeks
Number of subjects: 39
Study 16187007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily
Number of subjects: 9
Study 16187007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12494068 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (20 patients)
Number of subjects: 28
Study 12494068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 patients)
Number of subjects: 28
Study 10459816 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 25 mg/kg on the first day followed by 15 mg/kg od for 4 days
Number of subjects: 196
Study 10459816 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg od for 5 days
Number of subjects: 196
Study 10459816 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg od for 10 days
Number of subjects: 196
Study 10459816 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin dosing regimens
Number of subjects: 196
Study 10459816 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 24 h trough level at day 1
Number of subjects: 196
Study 7541236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg day‐1 for 7 days)
Number of subjects: 16
Study 7541236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 16
Study 7541236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2193200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 213
Study 2193200 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 213
Study 525840 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of a parasympatholytic agent
Number of subjects: 80
Study 525840 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy morphinic analgesia
Number of subjects: 80
Study 525840 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar block
Number of subjects: 80
Study 31881421 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophilic indoor environments
Number of subjects: 100
Study 31881421 — intervention group
Group type: COMPARATOR
Intervention: Non-biophilic environment
Number of subjects: 100
Study 31881421 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of biophilic environments
Number of subjects: 100
Study 30790323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided closed reduction and fixation
Number of subjects: 24
Study 30790323 — intervention group
Group type: COMPARATOR
Intervention: C-arm fluoroscopy-assisted fixation
Number of subjects: 24
Study 28133855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil (EVOO)
Number of subjects: 7403
Study 28133855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 7403
Study 28133855 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 7403
Study 26524046 — intervention group
Group type: EXPERIMENTAL
Intervention: Multigly‐cosidorum Tripterygium combined with rhIL‐11
Number of subjects: 75
Study 26524046 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 75
Study 24313873 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (intravenous and oral) administered on two occasions
Number of subjects: 0
Study 22075754 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-sintered Co-Cr structures with resin-modified glass-ionomer cement
Number of subjects: 48
Study 22075754 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-sintered Co-Cr structures with acrylic/urethane-based cement
Number of subjects: 48
Study 22075754 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-cast Co-Cr, Ni-Cr-Ti, and Pd-Au structures with self-adhesive cement
Number of subjects: 48
Study 22075754 — intervention group
Group type: EXPERIMENTAL
Intervention: All alloy groups
Number of subjects: 48
Study 18978501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis plant extract (Sativex)
Number of subjects: 17
Study 18978501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17427836 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy, specific dosage and duration not available
Number of subjects: 0
Study 15899725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion with sirolimus
Number of subjects: 22
Study 15899725 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus capsules with sirolimus
Number of subjects: 22
Study 12504399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine plus amodiaquine
Number of subjects: 316
Study 12504399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine plus artesunate
Number of subjects: 316
Study 12504399 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine/pyrimethamine alone
Number of subjects: 316
Study 11475731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassia angustifolia extract (CAE) enema administration
Number of subjects: 130
Study 7644655 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 scintigraphy
Number of subjects: 33
Study 7644655 — intervention group
Group type: COMPARATOR
Intervention: Gallium-67 scans
Number of subjects: 33
Study 2529294 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 86
Study 2529294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 155292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (IPTB) and disodium cromoglycate (DSCG)
Number of subjects: 18
Study 155292 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (IPTB)
Number of subjects: 18
Study 155292 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 18
Study 155292 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 18
Study 155292 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (beta-adrenergic agonist)
Number of subjects: 18
Study 31924637 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention including government engagement, health education, and targeting restaurants, home cooks, and primary school students and their families; implemented for 1 year.
Number of subjects: 2688
Study 31924637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2688
Study 29966229 — intervention group
Group type: EXPERIMENTAL
Intervention: Essence of Chicken (EC)
Number of subjects: 235
Study 29966229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 26520171 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% fluorometholone (FML)
Number of subjects: 41
Study 26520171 — intervention group
Group type: COMPARATOR
Intervention: Topical polyvinyl alcohol (PA)
Number of subjects: 41
Study 25231240 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrohysteropexy
Number of subjects: 124
Study 25231240 — intervention group
Group type: COMPARATOR
Intervention: Vaginal sacrospinous hysteropexy
Number of subjects: 124
Study 22488578 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-augmented diode laser therapy (808 nm) with ICG (2 mg/kg body weight) and diode laser pulses (50-110 J/cm²)
Number of subjects: 15
Study 22488578 — intervention group
Group type: COMPARATOR
Intervention: Diode laser therapy without ICG
Number of subjects: 15
Study 22488578 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL) treatment
Number of subjects: 15
Study 20413297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 402
Study 20413297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 402
Study 20413297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years with high VEGF
Number of subjects: 402
Study 20413297 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (overall population)
Number of subjects: 402
Study 18394111 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend social support
Number of subjects: 193
Study 18394111 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 193
Study 18394111 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend social support change factor
Number of subjects: 193
Study 18394111 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI change factor
Number of subjects: 193
Study 15816590 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 50
Study 15816590 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube Suction (LTS)
Number of subjects: 50
Study 11958302 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAT2
Number of subjects: 0
Study 11958302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestra
Number of subjects: 0
Study 11958302 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact Advanced
Number of subjects: 0
Study 11958302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver 5 (CS5)
Number of subjects: 0
Study 11958302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Autologous Transfusion System (CATS)
Number of subjects: 0
Study 11054990 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C; specific dosage and duration not mentioned
Number of subjects: 0
Study 11054990 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8790030 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) - dietary recommendations, antihypertensive drugs, counseling for smoking cessation
Number of subjects: 12866
Study 8790030 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study 8790030 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866
Study 1986601 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 27
Study 1986601 — intervention group
Group type: COMPARATOR
Intervention: Nylidrin
Number of subjects: 27
Study 6360750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen 600 mg, four times daily
Number of subjects: 50
Study 6360750 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg, four times daily
Number of subjects: 50
Study 6360750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen 600 mg, four times daily (combined data from Weeks 1 and 2)
Number of subjects: 50
Study 6360750 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg, four times daily (combined data from Weeks 1 and 2)
Number of subjects: 50
Study 31519360 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Lavage (PL)
Number of subjects: 86
Study 31519360 — intervention group
Group type: COMPARATOR
Intervention: Suction Only (SO)
Number of subjects: 86
Study 29315667 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary constraints between near-colliding links
Number of subjects: 0
Study 29315667 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Poisson-disk motion planner
Number of subjects: 0
Study 29315667 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for correlated protein motions
Number of subjects: 0
Study 26654956 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred activities in daily living intervention (CADL)
Number of subjects: 6
Study 25972101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (single intravenous dose)
Number of subjects: 500
Study 25972101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 500
Study 23217479 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of pre-operative antibiotics (cefuroxime sodium and metronidazole)
Number of subjects: 377
Study 23217479 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotics (same antibiotics as group A)
Number of subjects: 377
Study 23217479 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of pre-operative antibiotics (cefuroxime and metronidazole)
Number of subjects: 377
Study 20652627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone (400 mg or 800 mg once daily or 600 mg twice daily)
Number of subjects: 124
Study 20652627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 20652627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 124
Study 18520806 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly intravenous cetuximab (initial dose 400mg/m2; maintenance dose 250 mg/m2) with concomitant radiotherapy (64Gy/32 fractions/45 days)
Number of subjects: 12
Study 15637747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement
Number of subjects: 20
Study 15637747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15637747 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 12069179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic dysfunction (HD+) subgroup
Number of subjects: 26
Study 12069179 — intervention group
Group type: COMPARATOR
Intervention: Non-hepatic dysfunction (HD-) subgroup
Number of subjects: 26
Study 10431879 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin
Number of subjects: 154
Study 10431879 — intervention group
Group type: COMPARATOR
Intervention: Control (no ciprofloxacin)
Number of subjects: 154
Study 8776071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense training programme
Number of subjects: 121
Study 8776071 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate training programme
Number of subjects: 121
Study 8776071 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 121
Study 2246493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg twice daily
Number of subjects: 0
Study 2246493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6286734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril (5 or 10 mg) and hydrochlorothiazide (50 mg)
Number of subjects: 8
Study 6286734 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 or 10 mg)
Number of subjects: 8
Study 6286734 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg)
Number of subjects: 8
Study 6286734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30811444 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated core exercises (prone bridge, side bridge, back extension)
Number of subjects: 0
Study 30811444 — intervention group
Group type: COMPARATOR
Intervention: Integrated core exercises (lunges on stable surface, unstable surface, with external resistance)
Number of subjects: 0
Study 30811444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunges with elastic bands
Number of subjects: 0
Study 30811444 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable lunges
Number of subjects: 0
Study 28322359 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + acid etching
Number of subjects: 51
Study 28322359 — intervention group
Group type: COMPARATOR
Intervention: Acid etching
Number of subjects: 51
Study 25727718 — intervention group
Group type: EXPERIMENTAL
Intervention: BCRL group (n=15)
Number of subjects: 30
Study 25727718 — intervention group
Group type: EXPERIMENTAL
Intervention: No BCRL group (n=15)
Number of subjects: 30
Study 25727718 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 30
Study 25727718 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (n=30)
Number of subjects: 30
Study 25130995 — intervention group
Group type: COMPARATOR
Intervention: STAS (short-term androgen suppression with leuprorelin for 6 months and radiotherapy)
Number of subjects: 1071
Study 25130995 — intervention group
Group type: EXPERIMENTAL
Intervention: STAS plus zoledronic acid (4 mg every 3 months for 18 months, intravenously)
Number of subjects: 1071
Study 25130995 — intervention group
Group type: EXPERIMENTAL
Intervention: ITAS (intermediate-term androgen suppression with leuprorelin for 18 months and radiotherapy)
Number of subjects: 1071
Study 25130995 — intervention group
Group type: EXPERIMENTAL
Intervention: ITAS plus zoledronic acid
Number of subjects: 1071
Study 25130995 — intervention group
Group type: COMPARATOR
Intervention: STAS
Number of subjects: 1071
Study 25130995 — intervention group
Group type: EXPERIMENTAL
Intervention: STAS plus zoledronic acid
Number of subjects: 1071
Study 25130995 — intervention group
Group type: EXPERIMENTAL
Intervention: ITAS
Number of subjects: 1071
Study 22895556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine plus aclacinomycin/cytarabine (DAA)
Number of subjects: 20
Study 22895556 — intervention group
Group type: COMPARATOR
Intervention: Aclacinomycin/cytarabine (AA)
Number of subjects: 20
Study 19774307 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training with an electromechanical gait device
Number of subjects: 16
Study 19774307 — intervention group
Group type: COMPARATOR
Intervention: Treadmill or task-oriented gait training
Number of subjects: 16
Study 21611946 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G needle
Number of subjects: 127
Study 21611946 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G needle
Number of subjects: 127
Study 16143730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.23 mg/kg IV followed by 0.5 mg/kg infusion)
Number of subjects: 41
Study 16143730 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (0.25 mg/kg infusion)
Number of subjects: 41
Study 16143730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and Amphetamine (combined effects)
Number of subjects: 41
Study 16143730 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for ketamine)
Number of subjects: 41
Study 16143730 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for amphetamine)
Number of subjects: 41
Study 12355581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialon (Julphar, UAE)
Number of subjects: 24